Methylation of MGMT promoter does not predict response to temozolomide in patients with glioblastoma in Donostia Hospital

O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation status has been considered a prognostic factor in newly diagnosed glioblastoma (GBM). In this study, we evaluated the prognostic and predictive value of MGMT promoter methylation in patients with glioblastoma in Donostia Hospital....

詳細記述

保存先:
書誌詳細
出版年:Sci Rep
主要な著者: Egaña, Larraitz, Auzmendi-Iriarte, Jaione, Andermatten, Joaquin, Villanua, Jorge, Ruiz, Irune, Elua-Pinin, Alejandro, Aldaz, Paula, Querejeta, Arrate, Sarasqueta, Cristina, Zubia, Felix, Matheu, Ander, Samprón, Nicolas
フォーマット: Artigo
言語:Inglês
出版事項: Nature Publishing Group UK 2020
主題:
Article
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC7595088/
https://ncbi.nlm.nih.gov/pubmed/33116181
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41598-020-75477-9
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料